STAT3 and colorectal carcinoma: STAT3 activation in CRC is also associated with adverse clinical outcomes, supporting its potential role as a prognostic biomarker and a chemopreventive and/or therapeutic target (Morikawa et al., 2011); although, effectively inhibiting the activity of a transcriptional factor remains challenging due to their intracellular localization and lack of enzymatic activity.